Gene Name	Entrez ID	Drug Name	Chembl ID	Interaction Types	Sources	publications
ACE	1636	RAMIPRIL	CHEMBL1168	inhibitor	TdgClinicalTrial, GuideToPharmacologyInteractions, ChemblInteractions, TEND, DrugBank	11030016, 11752352, 11929321, 16398929
ACE	1636	TRANDOLAPRIL	CHEMBL1519	inhibitor	TdgClinicalTrial, GuideToPharmacologyInteractions, ChemblInteractions, TEND, DrugBank	11752352, 11929321, 11030016
ACE	1636	CAPTOPRIL	CHEMBL1560	inhibitor	PharmGKB, TdgClinicalTrial, GuideToPharmacologyInteractions, ChemblInteractions, NCI, TEND, DrugBank	11030016, 11752352, 16889963, 15236580, 17618628, 20014331, 11929321, 12424228, 12489813, 2442780, 2839262, 2875891, 3038284, 3320343, 3325392, 3937925, 6275810, 7042175, 8864563, 9863143
ACE	1636	INDOMETHACIN	CHEMBL6		NCI	3937925
ACE	1636	FOSINOPRIL	CHEMBL3039598	inhibitor	TdgClinicalTrial, GuideToPharmacologyInteractions, TEND
ACE	1636	IMIDAPRILAT	CHEMBL99701	inhibitor	GuideToPharmacologyInteractions
ACE	1636	QUINAPRILAT	CHEMBL1733	inhibitor	GuideToPharmacologyInteractions
ACE	1636	SPIRAPRILAT	CHEMBL579	inhibitor	GuideToPharmacologyInteractions
ACE	1636	ENALAPRILAT HYDRATE	CHEMBL1200697	inhibitor	ChemblInteractions
ACE	1636	SPIRAPRIL HYDROCHLORIDE	CHEMBL1200831	inhibitor	ChemblInteractions
ACE	1636	LISINOPRIL HYDRATE	CHEMBL1729579	inhibitor	ChemblInteractions
ACE	1636	BENAZEPRIL HYDROCHLORIDE	CHEMBL1694	inhibitor	ChemblInteractions
ACE	1636	LISINOPRIL	CHEMBL1237	inhibitor	PharmGKB, TdgClinicalTrial, GuideToPharmacologyInteractions, TEND, DrugBank	11752352, 17618628, 9506845, 11929321, 11030016
ACE	1636	OMAPATRILAT	CHEMBL289556		DrugBank	12487427, 10856268, 10598120, 12584671, 11588409
ACE	1636	RESCINNAMINE	CHEMBL1668	inhibitor	TdgClinicalTrial, TEND, DrugBank	16431399, 11752352, 17139284, 17016423
ACE	1636	SPIRAPRIL	CHEMBL431	inhibitor	TdgClinicalTrial, GuideToPharmacologyInteractions, TEND, DrugBank	16126915, 11752352, 20524801, 12613273, 11929321
ACE	1636	VASOPRESSIN	CHEMBL373742		NCI	6289972
ACE	1636	SPIRONOLACTONE	CHEMBL1393		PharmGKB
ACE	1636	BENAZEPRIL	CHEMBL838	inhibitor	TdgClinicalTrial, GuideToPharmacologyInteractions, TEND
ACE	1636	QUINAPRIL	CHEMBL1592		TdgClinicalTrial, TEND
ACE	1636	MOEXIPRIL	CHEMBL1165	inhibitor	TdgClinicalTrial, GuideToPharmacologyInteractions, TEND
ACE	1636	ENALAPRIL	CHEMBL578	inhibitor	TdgClinicalTrial, GuideToPharmacologyInteractions, TEND
ACE	1636	HYDROCHLOROTHIAZIDE	CHEMBL435		PharmGKB
ACE	1636	BENAZEPRILAT	CHEMBL1192519	inhibitor	GuideToPharmacologyInteractions
ACE	1636	TRANDOLAPRILAT	CHEMBL1201387	inhibitor	GuideToPharmacologyInteractions
ACE	1636	FOSINOPRIL SODIUM	CHEMBL3039596	inhibitor	ChemblInteractions
ACE	1636	CILAZAPRIL	CHEMBL515606	inhibitor	TdgClinicalTrial, GuideToPharmacologyInteractions, TEND, DrugBank	1382157, 1382161, 10398211, 11752352, 10446934, 10205231, 18423812
ACE	1636	PERINDOPRIL	CHEMBL1581	inhibitor	TdgClinicalTrial, GuideToPharmacologyInteractions, TEND
ACE	1636	CHEMBL3187812	CHEMBL3187812		TdgClinicalTrial
ACE	1636	ENALAPRILAT	CHEMBL577	inhibitor	GuideToPharmacologyInteractions
ACE	1636	FASIDOTRIL	CHEMBL2106226	inhibitor	GuideToPharmacologyInteractions
ACE	1636	FASIDOTRILAT	CHEMBL325055	inhibitor	GuideToPharmacologyInteractions
ACE	1636	PERINDOPRILAT	CHEMBL1201368	inhibitor	GuideToPharmacologyInteractions
ACE	1636	RAMIPRILAT	CHEMBL1201365	inhibitor	GuideToPharmacologyInteractions
ACE	1636	QUINAPRIL HYDROCHLORIDE	CHEMBL1201011	inhibitor	ChemblInteractions
ACE	1636	TEMOCAPRIL	CHEMBL2110627	inhibitor	DrugBank	8513851
ACE	1636	ENALAPRIL MALEATE	CHEMBL1200659	inhibitor	ChemblInteractions, NCI	3038326
ACE	1636	IMIDAPRIL	CHEMBL317094	inhibitor	PharmGKB, GuideToPharmacologyInteractions
ACE	1636	DESERPIDINE	CHEMBL1200515		TdgClinicalTrial, TEND
ACE	1636	CHEMBL1235767	CHEMBL1235767	inhibitor	GuideToPharmacologyInteractions
ACE	1636	MOEXIPRIL HYDROCHLORIDE	CHEMBL1200534	inhibitor	ChemblInteractions
ACE	1636	PERINDOPRIL ERBUMINE	CHEMBL1200343	inhibitor	ChemblInteractions
ACE	1636	PERINDOPRIL ARGININE	CHEMBL3544986	inhibitor	ChemblInteractions
ACE	1636	ZOFENOPRIL	CHEMBL331378	inhibitor	GuideToPharmacologyInteractions, DrugBank	17355163
ACE	1636	CANDOXATRIL	CHEMBL35084	inhibitor	TdgClinicalTrial, TEND, DrugBank	16642666, 11300648

Gene Name	Variant	Alleles	Chemical	Phenotype Category	Significance	Notes	Sentence	Publications	Annotation ID
ACE	rs1799752	ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC	salvianolic acid b	efficacy	yes	Patients homozygous for the 289BP ALU insertion ("I") allele were found to have a much better response to salvianolate then those who carry the del ("D") allele. Response was assessed by the decrease in the number or severity of angina attacks and nitroglycerine consumption. Genotype frequencies also significantly differed when comparing healthy controls (n=169) with those with coronary heart disease (n=153).	Genotype ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC is associated with increased response to salvianolic acid b in people with Coronary Disease as compared to genotypes ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del + del/del.	24827774	1451206568
ACE	rs1799752	del/del	captopril	efficacy	yes	99mTc-MAG3 clearance (MAG3cle) values increased with each addition of an ATA... allele, after treatment with captopril. MAG3cle provides an estimation of effective renal plasma flow (ERPF), and therefore of responsiveness to captopril treatment.	Genotype del/del is associated with decreased response to captopril in people with Diabetes Mellitus, Type 2 as compared to genotypes ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC + ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del.	19286758	982044530
ACE	rs1799752	del/del	captopril	efficacy	yes	Patients with the del/del genotype had steeper decline in glomerular filtration rate (GFR) compared to the other genotypes, indicating a decline in renal function.	Genotype del/del is associated with increased resistance to captopril in people with Diabetes Mellitus as compared to genotypes ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC + ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del.	8806248	982032925
ACE	rs1799752	del/del	captopril	efficacy	yes	The del/del genotype is associated with a increased mean pulmonary arterial pressure (mPAP; units = mmHg) and increased pulmonary vascular resistance (PVR; units = mmHg/l/min/m2) after exercise, as compared to the remaining genotypes. This indicates a decreased response to captopril.	Genotype del/del is associated with decreased response to captopril in men with Pulmonary Disease, Chronic Obstructive as compared to genotypes ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC + ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del.	12832683	982042579
ACE	rs1799752	ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC	captopril	efficacy	yes	The ATA.../ATA... genotype is associated with increased mixed venous oxygen tension (PvO2; units = mmHg) and decreased lactate concentration (units = mmol/l) after exercise, as compared to patients with the remaining genotypes. This indicates an increased response to captopril.	Genotype ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC is associated with increased response to captopril in men with Pulmonary Disease, Chronic Obstructive as compared to genotypes ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del + del/del.	12832683	982042629
ACE	rs1799752	ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC	captopril	efficacy	yes	Reduction in mean arterial blood pressure and albuminuria was significantly greater in those with the ATA.../ATA... genotype compared to the remaining genotypes. No significant differences in change of serum creatinine was seen between the groups. Patients were treated with captopril for 6 months.	Genotype ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC is associated with increased response to captopril in people with Diabetes Mellitus as compared to genotypes ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del + del/del.	9551410	982033238
ACE	rs1799752	del/del	enalapril	efficacy	yes	"There was a decrease in blood pressure in the patients carrying the DD genotype (SBP=18.5±8.1 mmHg, DBP=15.29±7.1 mmHg) rather than the ID (SBP=4.1±3.3 mmHg, DBP=9.1±3.5 mmHg) and II genotypes (SBP= 3.0±0.2 mmHg, DBP 0.11±6.1 mmHg) of the ACE gene."	Genotype del/del is associated with increased clinical benefit to enalapril or lisinopril in men with Hypertension as compared to genotypes ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC + ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del.	25002132	1451250000
ACE	rs1799752	del/del	enalapril	efficacy	yes	Patients with the del/del genotype showed greater improvement in left ventricular mass index and peak atrial systolic velocity:peak early diastolic velocity ratio, compared to those with the remaining genotypes. No significant changes were seen in deceleration time or isovolumic relaxation time. Enalapril administered for 12 months.	Genotype del/del is associated with increased response to enalapril in people with Essential hypertension as compared to genotypes ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC + ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del.	8986921	982033050
ACE	rs1799752	del/del	tacrolimus	dosage	no	All liver transplant recipients were given tacrolimus 2-3 days post liver transplantation. Weight adjusted dose and concentration to dose ratio (C/D) were the primary outcomes. Dose and C/D were calculated based on measurements taken on day 3, 7 and 14 post-transplantation as well as the the 1st, 3rd, 6th and 12th month post-transplantation. ACE genotype was not significantly associated with C/D of tacrolimus at any time point.	Genotype del/del is not associated with concentrations of tacrolimus in children with liver transplantation.	25310192	1185012329
ACE	rs4341	CG + GG	pravastatin	efficacy	yes	as measured by decreases in total cholesterol.	Genotypes CG + GG are associated with increased response to pravastatin as compared to genotype CC.	16103896	982045682
ACE	rs1799752	del/del	benazepril	efficacy	yes	Patients with the del/del genotype had significantly greater percentage reductions between baseline and 3 months of treatment in urinary excretion of protein and albumin, as compared to those with the remaining genotypes. This indicates a greater response to the antiproteinuric effects of benazepril and perindopril.	Genotype del/del is associated with increased response to benazepril or perindopril in people with Diabetes Mellitus as compared to genotypes ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC + ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del.	11007831	982042071
ACE	rs1799752	del/del	sertraline	efficacy	yes	as compared to fluoxetine. Patients with major depressive disorder were randomized to receive sertraline or fluoxetine. Depression severity determined w/ the 21-item Hamilton Rating Scale for Depression (HAMD-21) before and after the treatment. Response calculated based on 50 % reduction in the reported scores. Given allele frequencies were compared between treatment groups in the responsive patients only.	Genotype del/del is associated with increased response to sertraline in people with Depressive Disorder.	27262302	1448102319
ACE	rs1799752	del/del	interferon beta-1a	efficacy	yes	The subject were treated with interferon beta. Only in men showed the multiple forward regression analysis that the del/del genotype is associated with negative IFN-beta response.	Genotype del/del is associated with decreased response to interferon beta-1a in men Multiple Sclerosis.	28430710	1448615363
ACE	rs1799752	del	interferon beta-1a	efficacy	no	The subject were treated with interferon beta.	Allele del is not associated with response to interferon beta-1a in women Multiple Sclerosis as compared to allele ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC.	28430710	1448615370
ACE	rs8075924	TT	bupropion	efficacy	yes	Patients with the TT genotype show a smaller reduction in HAMD17 scores as compared to patients with the CC or CT genotypes.	Genotype TT is associated with decreased response to bupropion in people with Depressive Disorder, Major as compared to genotypes CC + CT.	22947179	1450814589
ACE	rs4291	TT	sertraline	efficacy	no	as compared to fluoxetine. Patients with major depressive disorder were randomized to receive sertraline or fluoxetine. Depression severity determined w/ the 21-item Hamilton Rating Scale for Depression (HAMD-21) before and after the treatment. Response calculated based on 50 % reduction in the reported scores. Given allele frequencies were compared between treatment groups in the responsive patients only.	Genotype TT is not associated with response to sertraline in people with Depressive Disorder.	27262302	1448102401
ACE	rs4331	GG	atenolol	efficacy	no	No differences in the change in systolic blood pressure (SBP) or diastolic blood pressure (DBP) was seen between genotypes, between baseline and 12 weeks of treatment. ANOVA was used, so p-value refers to associations when comparing all three genotypes against each other.	Genotype GG is not associated with response to atenolol in people with Hypertension as compared to genotypes AA + AG.	14700505	982042960
ACE	rs4331	GG	irbesartan	efficacy	no	No differences in the change in systolic blood pressure (SBP) or diastolic blood pressure (DBP) was seen between genotypes, between baseline and 12 weeks of treatment. ANOVA was used, so p-value refers to associations when comparing all three genotypes against each other.	Genotype GG is not associated with response to irbesartan in people with Hypertension as compared to genotypes AA + AG.	14700505	982043003
ACE	rs4331	AA	fluvastatin	efficacy	no	as measured by decreases in LDL-cholestrol. No significant association was seen between all three genotypes and response.	Genotype AA is not associated with response to fluvastatin as compared to genotype GG.	16103896	982045842
ACE	rs4341	CC	fluvastatin	efficacy	no	as measured by decreases in LDL-cholestrol. No significant association was seen between all three genotypes and response.	Genotype CC is not associated with response to fluvastatin as compared to genotype GG.	16103896	982045947
ACE	rs4343	GG	sertraline	efficacy	no	as compared to fluoxetine. Patients with major depressive disorder were randomized to receive sertraline or fluoxetine. Depression severity determined w/ the 21-item Hamilton Rating Scale for Depression (HAMD-21) before and after the treatment. Response calculated based on 50 % reduction in the reported scores. Given allele frequencies were compared between treatment groups in the responsive patients only.	Genotype GG is not associated with response to sertraline in people with Depressive Disorder.	27262302	1448102384
ACE	rs4344	AA + GG	ramipril	efficacy	yes	This SNP was also reported as ACE G12269A. This SNP was in linkage disequilibrium with the ACE Ins/Del (rs1799752), D' = .98, and rs4359, D' = .88. Patients homozygous for this SNP (AA or GG) responded to ACE inhibitor treatment (reached target blood pressure) almost twice as fast as patients heterozygous (AG) for this SNP.	Genotypes AA + GG are associated with increased response to ramipril in people with Hypertension as compared to genotype AG.	17885551	982048062
ACE	rs4359	CC + TT	ramipril	efficacy	yes	This SNP was also reported as ACE C17888T. This SNP was in linkage disequilibrium with rs4344, D' = .88. Patients homozygous for this SNP (CC or TT) responded to ACE inhibitor treatment (reached target blood pressure) faster than patients heterozygous (CT) for this SNP.	Genotypes CC + TT are associated with increased response to ramipril in people with Hypertension as compared to genotype CT.	17885551	982048078
ACE	rs4363	AA + AG	ramipril	efficacy	no	This SNP was also reported as ACE G20037A. No association was seen between this SNP and time to target blood pressure.	Genotypes AA + AG are not associated with increased response to ramipril in people with Hypertension as compared to genotype GG.	17885551	982048083
ACE	rs1799752	del/del	captopril	efficacy	yes	Response indicated by decrease in mean arterial pressure (MAP in mmHg) and total renal vascular resistance (RVR in mmHg/ml/min), and increase in effective renal plasma flow (ERPF). Individuals with the del/del allele showed significantly less of a change in MAP, RVR and ERPF compared to the remaining genotypes.	Genotype del/del is associated with decreased response to captopril in healthy individuals as compared to genotypes ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC + ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del.	9069453	982033131
ACE	rs1799752	ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC	bradykinin	efficacy	no	The SNP was presented as ACE I/D. Bradykinin induced similar vasodilation in both genotype groups. No subjects with the ID genotype were included in this study.	Genotype ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC is not associated with increased response to bradykinin in healthy individuals as compared to genotype del/del.	10710136	1183491834
ACE	rs1799752	del/del	captopril	efficacy	yes	Patients with the del/del genotype had decreased change in mean arterial pressure (MAP) compared to those with other genotypes. No significant difference in glomerular filtration rate (GFR) change was seen between genotypes.	Genotype del/del is associated with decreased response to captopril in people with Heart Failure as compared to genotypes ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC + ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del.	9869506	982033375
ACE	rs1799752	ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC	acetylcholine	efficacy	yes	A gene dose effect was observed in that vasodilation increased with the presence of the insertion. (del/del < del/ins < ins/ins)	Allele ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC is associated with increased response to acetylcholine or nitroprusside in healthy individuals as compared to allele del.	10334805	982034681
ACE	rs1799752	ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC	verapamil	efficacy	no	Genotype did not significantly affect vasodilation due to treatment with verapamil, though there was a trend toward having the deletion cause less vasodilation in a gene dose effect (del/del < del/ins < ins/ins).	Allele ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC is not associated with increased response to verapamil in healthy individuals as compared to allele del.	10334805	982034860
ACE	rs1799752	ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC	norepinephrine	efficacy	no	Genotype did not affect vasoconstriction due to treatment with norepinephrine or N-monomethyl-L-arginine.	Allele ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC is not associated with increased response to norepinephrine in healthy individuals as compared to allele del.	10334805	982034878
ACE	rs1799752	del/del	candesartan	efficacy	no	Response was defined as a diastolic blood pressure of < 85 mmHg at follow-up after 4 weeks of treatment.	Genotype del/del is not associated with response to candesartan in people with Hypertension as compared to genotypes ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC + ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del.	12065207	982034052
ACE	rs1799752	del/del	enalapril	efficacy	no	No statistical analyses were done comparing del/del against the remaining genotypes. However, patients with the del/del genotype showed no significant changes in systolic blood pressure (BP), diastolic BP or 24-hour urinary protein excretion, while those with the other genotypes did see significant changes in these values at 10 weeks and 6 months into treatment. This suggests that enalapril reduces BP and proteinuria less efficiently in those with the del/del genotype.	Genotype del/del is associated with decreased response to enalapril in people with glomerular disease as compared to genotypes ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC + ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del.	9661139	982033349
ACE	rs1799752	del/del	pravastatin	efficacy	yes	Described as DD vs II/ID. The DD genotype was associated with significantly deteriorated endothelial function in dilated and normal coronary segments. Pravastatin had a beneficial effect in patients with the DD genotype.	Genotype del/del is associated with response to pravastatin in people with non-hypercholesterolaemic patients scheduled for angioplasty as compared to genotypes ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC + ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del.	12695469	982036636
ACE	rs1799752	del/del	fluvastatin	efficacy	yes	Compared to ins/ins and ins/del genotypes. As determined by measuring clinical outcome (angiographical change) - patients with the del/del genotype were less likely to have progression and more likely to have regression of disease. Please note; specific mapping of this variant was not given - it was only described as ACE I/D polymorphism.	Genotype del/del is associated with increased response to fluvastatin in people with Coronary Artery Disease as compared to genotype ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC.	10636265	982036510
ACE	rs1799752	del/del	fluvastatin	efficacy	yes	Compared to ins/ins and ins/del genotypes. As determined by measuring plasma lipid levels - patients with the del/del genotype had a greater reduction in plasma levels of total cholestrol, LDL-C, and apoB. These reductions were in the order del/del > del/insertion > insertion/insertion. Please note; specific mapping of this variant was not given - it was only described as ACE I/D polymorphism.	Genotype del/del is associated with increased response to fluvastatin in people with Coronary Artery Disease as compared to genotype ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC.	10636265	982036494
ACE	rs1799752	del/del	atenolol	efficacy	yes	Patients with the del/del genotype had a steeper decline in glomerular filtration rate (GFR) over 3-4 years (expressed as slope of GFR versus time), indicating a decline in renal function. 41 patients were given atenolol and 40 were given enalapril.	Genotype del/del is associated with increased resistance to atenolol and enalapril in people with Kidney Diseases as compared to genotypes ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC + ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del.	8538349	982032850
ACE	rs1799752	ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC	enalapril	efficacy	yes	Patients with the ATA.../ATA... genotype had greater percent improvement in brachial artery flow mediated dilation (FMD; a way to analyze endothelial function) after enalapril or losartan treatment for 5 months, as compared to those with the remaining genotypes. Please note that patients underwent coronary artery bypass graft surgery 2 months into treatment with these drugs.	Genotype ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC is associated with increased response to enalapril and losartan in men with Coronary Disease as compared to genotypes ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del + del/del.	16020596	982043371
ACE	rs1799752	ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del + del/del	enalapril	efficacy	yes	Presence of the del allele was associated with greater improvement in microvascular dilation (in patients with an initially depressed response to acetylcholine), and acetylcholine-mediated epicardial coronary constriction in patients taking enalaprilat (enalapril), as compared to those with the ATA.../ATA... genotype.	Genotypes ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del + del/del are associated with increased response to enalapril in people with Arteriosclerosis as compared to genotype ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC.	10880412	982041046
ACE	rs1799752	del/del	benazepril	efficacy	yes	Patients with the del/del genotype had a greater percent reduction in left ventricular mass index (units = g/m2), between baseline and 24 months of treatment, as compared to patients with the remaining genotypes.	Genotype del/del is associated with increased response to benazepril in people with Essential hypertension as compared to genotypes ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC + ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del.	15788353	982043310
ACE	rs1799752	ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC	lisinopril	efficacy	no	This SNP was presented as ACE I/D. Patients homozygous for the II genotype showed a much greater benefit (a significantly lower increase in albumin excretion ratio) from treatment with lisinopril as compared to patients carrying the D allele.	Genotype ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC is associated with increased response to lisinopril in people with Diabetes Mellitus, Type 1 as compared to genotype del/del.	9726242	1183491887
ACE	rs1799752	ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC	quinapril	efficacy	no	This SNP was presented as ACE I/D. I homozygotes had a nonsignificant trend towards greater minimal lumen diameter, lower late lumen loss, and lower restenosis rates after percutaneous coronary intervention as compared to patients carrying the del allele.	Genotype ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC is not associated with increased response to quinapril in people with Coronary Artery Disease as compared to genotypes ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del + del/del.	11849656	982048004
ACE	rs1799752	del/del	bumetanide	efficacy	yes	Subjects homozygous for the del allele had increased urinary excretion of calcium as compared to ATA.../ATA... homozygotes, during the 24 hours after drug administration.	Genotype del/del is associated with increased response to bumetanide, furosemide and torasemide in healthy individuals as compared to genotype ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC.	20877298	982045391
ACE	rs1799752	del/del	lisinopril	efficacy	no	No significant change in mean arterial pressure (MAP) or glomerular filtration rate (GFR) was seen between genotypes.	Genotype del/del is not associated with response to lisinopril in people with Heart Failure as compared to genotypes ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC + ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del.	9869506	982033386
ACE	rs1799752	ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC	angiotensin II	efficacy	no	The SNP was presented as ACE I/D. Infusion of angiotensin II yielded similar responses in both genotype groups. No subjects with the ID genotype were included in this study.	Genotype ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC is not associated with increased response to angiotensin II in healthy individuals as compared to genotype del/del.	10710136	1183491839
ACE	rs1799752	ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC	losartan	efficacy	no	This SNP was presented as ACE I/D. No differences in systemic hemodynamics was seen between genotype groups.	Allele ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC is not associated with increased response to losartan in people with Liver Cirrhosis as compared to allele del.	15743363	1144953742
ACE	rs1799752	ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC	atenolol	efficacy	no	No significant differences in the change in diastolic or systolic blood pressure after 3 months of treatment were seen between the genotypes.	Genotype ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC is not associated with response to atenolol in people with Hypertension as compared to genotypes ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del + del/del.	11593098	1183615565
ACE	rs1799752	del/del	benazepril	efficacy	no	No significant difference in the change in systolic blood pressure (SBP), diastolic blood pressure (DBP), pulse pressure (PP), heart rate (HR), left ventricular diastolic dimension (LVDd), interventricular septal thickness (IVST), or left ventricular posterior well thickness (LVPWT) between genotypes was seen, between baseline and 24 months of treatment.	Genotype del/del is not associated with response to benazepril in people with Essential hypertension as compared to genotypes ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC + ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del.	15788353	982043336
ACE	rs1799752	del/del	losartan	efficacy	yes	This SNP was presented as ACE I/D. Patients with Type II Diabetes Mellitus that also had macroalbuminuria with the DD genotype had a better response to losartan as compared to patients carrying the I allele, or with normoalbuminuria.	Genotype del/del is associated with increased response to losartan in people with Diabetes Mellitus, Type 2 as compared to genotypes ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC + ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del.	20830509	1183491316
ACE	rs1799752	ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del + del/del	quinapril	efficacy	yes	This SNP was presented as ACE I/D. Patients carrying the D allele showed significantly larger minimal lumen diameter six months after coronary stent implantation as compared to patients with the II genotype.	Genotypes ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del + del/del are associated with increased response to quinapril in people with Coronary Artery Disease as compared to genotype ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC.	11954942	1000539568
ACE	rs1799752	ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC	angiotensin II	efficacy	no	The SNP was presented as ACE I/D. Administration of losartan significantly inhibited the effects of angiotensin II, but this inhibition was similar in both genotype groups. No subjects with the ID genotype were included in this study.	Genotype ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC is not associated with increased response to angiotensin II and losartan in healthy individuals as compared to genotype del/del.	10710136	1183491842
ACE	rs1799752	ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC	irbesartan	efficacy	yes	Patients with the ATAC.../ATAC... genotype had a greater reduction in diastolic blood pressure after 3 months of treatment with irbesartan, compared to those with the ATAC.../del or del/del genotype. No significant difference was seen for systolic blood pressure.	Genotype ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC is associated with increased response to irbesartan in people with Hypertension as compared to genotypes ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del + del/del.	11593098	1183615560
ACE	rs1799752	del/del	losartan	efficacy	no	This SNP was reported as ACE I/D. Only patients homozygous for either allele (II or DD) were recruited for this study. Subjects were randomized to receive either placebo or losartan during a 10-week physical training program. While subjects with the DD genotype showed greater increases in left ventricular mass as compared to patients with the II genotype, no difference was seen between patients receiving losartan as compared to patients receiving placebo.	Genotype del/del is not associated with increased response to losartan in healthy individuals as compared to genotype ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC.	11208681	1043880833
ACE	rs1799752	del/del	captopril	efficacy	yes	This SNP was presented as ACE I/D. Patients with Type II Diabetes Mellitus that were normoalbuminuric with the DD genotype had a better response to captopril as compared to patients carrying the I allele, or with macroalbuminuria.	Genotype del/del is associated with increased response to captopril in people with Diabetes Mellitus, Type 2 as compared to genotypes ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC + ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del.	20830509	1183491329
ACE	rs1799752	ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC	nifedipine	efficacy	no	This SNP was presented as ACE I/D. While nifedipine administration significantly decreased mean pulmonary arterial pressure in all three genotype groups (II, ID, DD) compared to treatment with placebo, there was no difference in the magnitude of decrease between groups. Nifedipine also did not decrease pulmonary vascular resistance or oxygen delivery as compared to placebo.	Genotype ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC is not associated with increased response to nifedipine in men with Pulmonary Disease, Chronic Obstructive as compared to genotypes ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del + del/del.	15233837	1043858910
ACE	rs1799752	del/del	quinapril	efficacy	yes	This SNP was presented as ACE I/D. Patients homozygous for the D allele showed lesser vasoconstriction in response to Angiotensin II as compared to patients carrying the I allele. When treated with quinapril, patients homozygous for the D allele showed similar vasoconstriction as patients carrying the I allele. No effect of quinapril was seen on patients carrying the I allele.	Genotype del/del is associated with increased response to quinapril as compared to genotypes ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC + ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del.	15526248	1018613244